This content from the 2020 ASCRS Virtual Annual Meeting is only available to ASCRS members. To log in, click the teal "Login" button in the upper right-hand corner of this page.
To evaluate the predictability, reproducibility, efficacy, reliability and Safety of this innovative NON-invasive management for Presbyopes.
Prospective proof of concept of the results in Pseudoaccommodation and Physiologic Accommodation (subjective and objectively (with HD Analyzer, iTracey, OCT, UBM and Scheimpflug)), refraction, visual acuity corrected and uncorrected for far and near distance, refractive change, pupil size and dynamism (Photopic and Scotopic), endothelial cell count, IOP, Keratometry and ACD using the FOV Tears (EyeFocus) binocularly (not MONOVISION).
Pilot Study of 20 patients who received FOV Tears 9; ave 49,65 yo range 41/ 57, the measurements were taken previously, half an hour, 1, 2, 3, 4 and 5 hours later and 1 week and 1 month after. Prospective study of more than 540 patients who are using the drops constantly, the results of their first and second follow-up months later. Globally improve 1 line Far vision and 3 for Near and 1-2 additional lines with continuous use and extraordinary for Intermediate increase 0,75 D in Accommodation Amplitude initially, increasing up to 1,50 D; mild decrease of Pupil Size in Scotopic conditions and no change in Photopic but totally active, mild Myopic shift only in the first hour (-0,12 Diops).
This is a promising, physiologic NON-invasive and adjuvant solution for Presbyopia patients; generating enough independence of glasses for the most activities in the normal life of the patients with no risks neither secondary effects, incredible improve in intermediate vision.